These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 18065132

  • 21. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1).
    Addis A, Loebstein R, Koren G, Einarson TR.
    Eur J Clin Pharmacol; 1999 Mar; 55(1):1-6. PubMed ID: 10206077
    [Abstract] [Full Text] [Related]

  • 22. Combined therapy with deferoxamine and deferiprone.
    Kattamis A.
    Ann N Y Acad Sci; 2005 Mar; 1054():175-82. PubMed ID: 16339663
    [Abstract] [Full Text] [Related]

  • 23. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A, Kleanthous M, Kontoghiorghes GJ.
    Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
    [Abstract] [Full Text] [Related]

  • 24. Oral iron chelators.
    Cappellini MD, Pattoneri P.
    Annu Rev Med; 2009 Nov; 60():25-38. PubMed ID: 19630568
    [Abstract] [Full Text] [Related]

  • 25. Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.
    Jirasomprasert T, Morales NP, Limenta LM, Sirijaroonwong S, Yamanont P, Wilairat P, Fucharoen S, Chantharaksri U.
    Free Radic Res; 2009 May; 43(5):485-91. PubMed ID: 19353420
    [Abstract] [Full Text] [Related]

  • 26. Use of deferiprone for the treatment of hepatic iron storage disease in three hornbills.
    Sandmeier P, Clauss M, Donati OF, Chiers K, Kienzle E, Hatt JM.
    J Am Vet Med Assoc; 2012 Jan 01; 240(1):75-81. PubMed ID: 22171759
    [Abstract] [Full Text] [Related]

  • 27. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec 01; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

  • 28. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).
    Berdoukas V, Bohane T, Eagle C, Lindeman R, DeSilva K, Tobias V, Painter D, Fraser I.
    Transfus Sci; 2000 Dec 01; 23(3):239-40. PubMed ID: 11099900
    [No Abstract] [Full Text] [Related]

  • 29. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
    Santos MA, Gama S, Gil M, Gano L.
    Hemoglobin; 2008 Dec 01; 32(1-2):147-56. PubMed ID: 18274992
    [Abstract] [Full Text] [Related]

  • 30. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Dec 01; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 31. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Br J Haematol; 2009 Apr 01; 145(2):245-54. PubMed ID: 19236376
    [Abstract] [Full Text] [Related]

  • 32. Iron mobilization using chelation and phlebotomy.
    Flaten TP, Aaseth J, Andersen O, Kontoghiorghes GJ.
    J Trace Elem Med Biol; 2012 Jun 01; 26(2-3):127-30. PubMed ID: 22565013
    [Abstract] [Full Text] [Related]

  • 33. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G.
    Clin Pharmacol Ther; 1994 Jan 01; 55(1):70-5. PubMed ID: 8299320
    [Abstract] [Full Text] [Related]

  • 34. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 35. Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience.
    Zachariah M, Tony S, Bashir W, Al Rawas A, Wali Y, Pathare A.
    Pediatr Hematol Oncol; 2013 Mar 10; 30(2):104-12. PubMed ID: 23363369
    [Abstract] [Full Text] [Related]

  • 36. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
    Calvaruso G, Vitrano A, Di Maggio R, Ballas S, Steinberg MH, Rigano P, Sacco M, Telfer P, Renda D, Barone R, Maggio A, Investigators of the Multicenter Randomized Clinical Trial of Deferiprone versus Deferoxamine in Sickle-Cell-Disease.
    Blood Cells Mol Dis; 2014 Dec 10; 53(4):265-71. PubMed ID: 24814618
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M, Ali W, Anwar M, Waqar A, Khan MN, Ijaz A, Hussain T, Hussain S.
    J Ayub Med Coll Abbottabad; 2005 Dec 10; 17(4):12-5. PubMed ID: 16599026
    [Abstract] [Full Text] [Related]

  • 38. Combined versus monotherapy or concurrent therapy for treatment of thalassaemia.
    Song TS, Hsieh YW, Peng CT, Chen TL, Lee HZ, Chung JG, Hour MJ.
    In Vivo; 2014 Dec 10; 28(4):645-9. PubMed ID: 24982236
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y, Tzanetea R, Konstantopoulos K, Simitzis S, Zervas C, Kyriaki P, Kavouklis M, Aessopos A, Sakellaropoulos N, Karagiorga M, Kalotychou V, Loukopoulos D.
    Haematologica; 2000 Feb 10; 85(2):115-7. PubMed ID: 10681716
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.